BioWorld Asia

Jan. 22, 2003

View Archived Issues

Future Drugs Could Disrupt Protein Biosynthesis In Cancer

Procognia Closes $4M Round, Acquires Sense Proteomic Ltd.

Cyclacel Starts Phase II Trials Of Small-Molecule CDK Inhibitor

EU Leaders Support Worldwide Ban On Reproductive Cloning

ReNeuron Shares Drop On Failed Phase II Trials Of Lead Product

Second Complication Arises In French Gene Therapy Trial

Xenova Paying $1M For Rights To Two Addiction Vaccines

Adebag Planning Biotechnology Cluster In Southeastern France

Cerep Collaborates With Pfizer On BioPrint Database, Software

Other News To Note

Biolipox Raises EUR21M To Fund Drug Discovery, Development

Swedish drug discovery and development firm Biolipox AB raised €21 million in a second-round financing led by the Paris office of Apax Partners. (BioWorld International) Read More

U.S. Officials Step Up Threats Over European Ban On GM Crops

Today's news in brief

BioWorld

BioWorld briefs for Dec. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 24, 2024.

Illustration of neurons with Lewy bodies

Enhanced Cognition: Lewy body dementia phase II pumps stock

BioWorld

Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Lab glassware and antibodies art concept

Probing bidirectional cancer-autoimmune link can yield new targets

BioWorld Science

Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s...